Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 11, 2012, Pages 1343-1350

  Kim, D Y ^a,b   Ryu, H J ^a,b   Choi, J Y ^a   Park, J Y ^a,b   Lee, D Y ^a   Kim, B K ^a,b   Kim, S U ^a,b   Ahn, S H ^a,b   Chon, C Y ^a   Han, K H ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Liver Cirrhosis Clinical Research Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; IODINATED POPPYSEED OIL;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DRUG UPTAKE; FEMALE; HUMAN; INOPERABLE CANCER; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PATIENT CODING; PORTAL VEIN OBSTRUCTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIODIAGNOSIS; SURVIVAL PREDICTION; SURVIVAL RATE; TREATMENT FAILURE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; ETHIODIZED OIL; FEMALE; HUMANS; IODIZED OIL; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84860508287     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05089.x     Document Type: Article

References (36)

1. El-Serag HB,. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002; 35 (Suppl. 2): S72-8. (Pubitemid 35278644)
2. Jarnagin WR, Gonen M, Fong Y, et al,. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg 2002; 236: 397-406.
3. Imamura H, Seyama Y, Kokudo N, et al,. One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg 2003; 138: 1198-206. (Pubitemid 37392393)
4. Doyon D, Mouzon A, Jourde AM, Regensberg C, Frileux C,. Hepatic, arterial embolization in patients with malignant liver tumours. Ann Radiol (Paris) 1974; 17: 593-603.
5. Matui O, Miyayama S, Sanada J, et al,. Interventional oncology: new options for interstitial treatments and intravascular approaches: superselective TACE using iodized oil for HCC: rationale, technique and outcome. J Hepatobiliary Pancreat Sci 2010; 17: 407-9.
6. Konno T, Maeda H, Iwai K, et al,. Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur J Cancer Clin Oncol 1983; 19: 1053-65. (Pubitemid 13045311)
7. Ohishi H, Uchida H, Yoshimura H, et al,. Hepatocellular carcinoma detected by iodized oil. Use of anticancer agents. Radiology 1985; 154: 25-9. (Pubitemid 15196278)
8. Llovet JM, Bruix J,. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-42. (Pubitemid 36152543)
9. Bronowicki JP, Vetter D, Dumas F, et al,. Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year study of 127 French patients. Cancer 1994; 74: 16-24. (Pubitemid 24187604)
10. Takayasu K, Arii S, Ikai I, et al,. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131: 461-9. (Pubitemid 44142456)
11. Stefanini GF, Amorati P, Biselli M, et al,. Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. An Italian experience. Cancer 1995; 75: 2427-34.
12. Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K,. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer 2010; 116: 5452-60.
13. Lencioni R, Chen XP, Dagher L, Venook AP,. Treatment of intermediate/advanced heaptocellular carcinoma in the clinic: how can outcomes be improved? Oncologist 2010; 15 (Suppl. 4): 42-52.
14. Llad L, Virgili J, Figueras J, et al,. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer 2000; 88: 50-7. (Pubitemid 30027678)
15. O'Suilleabhain CB, Poon RTP, Yong JL, Ooi GC, Tso WK, Fan ST,. Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Br J Surg 2003; 90: 325-31. (Pubitemid 36324112)
16. Liem MS, Poon RT, Lo C, Tso W, Fan S,. Outcome of transarterial chemoembolization in patients with inoperable hepatocellular carcinoma eligible for radiofrequency ablation. World J Gastroenterol 2005; 11: 4465-71. (Pubitemid 41150384)
17. Lee HS, Kim KM, Yoon JH, et al,. Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study. J Clin Oncol 2002; 20: 4459-65. (Pubitemid 35334758)
18. Shim JH, Kim KM, Lee YJ, et al,. Complete necrosis after transarterial chemoembolization could predict prolonged survival in patients with recurrent intrahepatic hepatocellular carcinoma after curative resection. Ann Surg Oncol 2010; 17: 869-77.
19. Riaz A, Miller FH, Kulik LM, et al,. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA 2010; 303: 1062-9.
20. Cabibbo G, Genco C, Di Marco V, et al,. Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolization. Aliment Pharmacol Ther 2011; 34: 196-204.
21. Therasse P, Arbuck SG, Eisenhauer EA, et al,. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
22. Sala M, Llovet JM, Vilana R, et al,. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004; 40: 1352-60. (Pubitemid 39657009)
23. th edition) for patients with hepatocellular carcinoma: a validation analysis. Hepatology 2002; 24: 395-403. (Pubitemid 36002129)
24. Bruix J, Sherman M, Llovet JM, et al,. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-30. (Pubitemid 32844200)
25. Maleux G, van Malenstein H, Vandecaveye V, et al,. Transcatheter chemoembolization of unresectable hepatocellular carcinoma: current knowledge and future directions. Dig Dis 2009; 27: 157-63.
26. Laura L, Joan V, Joan F, et al,. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer 2000; 88: 50-7.
27. Koniaris LG, Levi DM, Pedroso FE, et al,. Is surgical resection superior to transplantation in the treatment of hepatocellular carcinoma? Ann Surg 2011; 254: 527-37.
28. Arii S, Yamaoka Y, Futagawa S, et al,. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. Hepatology 2000; 32: 1224-9.
29. Shim SJ, Seong J, Han K-H, et al,. Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. Liver Int 2005; 25: 1189-96. (Pubitemid 41782564)
30. Rossi S, Garbagnati F, Lencioni R, et al,. Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology 2000; 217: 119-26. (Pubitemid 33097587)
31. Malagari K, Chatzimichaeal K, Alexopoulou E, et al,. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Interv Radiol 2008; 31: 269-80.
32. Lammer J, Malagari K, Vogl T, et al,. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Interv Radiol 2010; 33: 41-52.
33. Cabrera R, Nelson DR,. Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther 2010; 31: 461-76.
34. Sangro B, Carpanese L, Cianni R, et al,. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 2011; 54: 868-78.
35. Cabrera R, Pannu DS, Caridi J, et al,. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Aliment Pharmacol Ther 2011; 34: 205-13.
36. Kudo M, Imanaka K, Chida N, et al,. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011; 47: 2117-27.